BG108131A - Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders - Google Patents

Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders

Info

Publication number: BG108131A
Authority: BG; Bulgaria
Prior art keywords: vitamin; treatment; estrogen; receptor partial; nicotine receptor
Prior art date: 2001-03-01

Application number

BG108131A

Other languages

Bulgarian (bg)

English (en)

Inventor

Anabella Villalobos

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-01

Filing date

2003-08-25

Publication date

2004-09-30

2003-08-25 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2004-09-30 Publication of BG108131A publication Critical patent/BG108131A/xx

Links

208000010877 cognitive disease Diseases 0.000 title abstract 4
239000000262 estrogen Substances 0.000 title abstract 4
229940011871 estrogen Drugs 0.000 title abstract 3
229960002715 nicotine Drugs 0.000 title abstract 3
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title abstract 3
239000004031 partial agonist Substances 0.000 title abstract 3
239000000556 agonist Substances 0.000 title 1
229940088594 vitamin Drugs 0.000 title 1
229930003231 vitamin Natural products 0.000 title 1
235000013343 vitamin Nutrition 0.000 title 1
239000011782 vitamin Substances 0.000 title 1
150000003722 vitamin derivatives Chemical class 0.000 title 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 4
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 2
208000030886 Traumatic Brain injury Diseases 0.000 abstract 2
229930003427 Vitamin E Natural products 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 2
229940125425 inverse agonist Drugs 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 2
239000000333 selective estrogen receptor modulator Substances 0.000 abstract 2
230000009529 traumatic brain injury Effects 0.000 abstract 2
229940046009 vitamin E Drugs 0.000 abstract 2
235000019165 vitamin E Nutrition 0.000 abstract 2
239000011709 vitamin E Substances 0.000 abstract 2
208000030507 AIDS Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
206010012289 Dementia Diseases 0.000 abstract 1
201000010374 Down Syndrome Diseases 0.000 abstract 1
208000023105 Huntington disease Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
206010044688 Trisomy 21 Diseases 0.000 abstract 1
201000004810 Vascular dementia Diseases 0.000 abstract 1
230000007000 age related cognitive decline Effects 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
230000019771 cognition Effects 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
206010027175 memory impairment Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
208000027061 mild cognitive impairment Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychology (AREA)
Virology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BG108131A 2001-03-01 2003-08-25 Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders BG108131A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27256601P	2001-03-01	2001-03-01
PCT/IB2002/000515 WO2002069948A1 (en)	2001-03-01	2002-02-20	Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders

Publications (1)

Publication Number	Publication Date
BG108131A true BG108131A (en)	2004-09-30

Family

ID=23040351

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108131A BG108131A (en)	2001-03-01	2003-08-25	Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders

Country Status (33)

Country	Link
US (2)	US20020193360A1 (cs)
EP (1)	EP1363606A1 (cs)
JP (1)	JP2004527500A (cs)
KR (1)	KR20030076717A (cs)
CN (1)	CN1494422A (cs)
AP (1)	AP2002002465A0 (cs)
AR (1)	AR033425A1 (cs)
BG (1)	BG108131A (cs)
BR (1)	BR0207802A (cs)
CA (1)	CA2439581A1 (cs)
CR (1)	CR7059A (cs)
CZ (1)	CZ20032338A3 (cs)
DO (1)	DOP2002000345A (cs)
EA (1)	EA200300854A1 (cs)
EC (1)	ECSP034759A (cs)
EE (1)	EE200300422A (cs)
GT (1)	GT200200039A (cs)
HU (1)	HUP0303448A3 (cs)
IL (1)	IL157465A0 (cs)
IS (1)	IS6905A (cs)
MA (1)	MA26999A1 (cs)
MX (1)	MXPA03007834A (cs)
NO (1)	NO20033821L (cs)
NZ (1)	NZ527397A (cs)
OA (1)	OA12554A (cs)
PA (1)	PA8540701A1 (cs)
PE (1)	PE20020927A1 (cs)
PL (1)	PL364081A1 (cs)
SK (1)	SK10752003A3 (cs)
TN (1)	TNSN02018A1 (cs)
UY (1)	UY27188A1 (cs)
WO (1)	WO2002069948A1 (cs)
ZA (1)	ZA200306193B (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6825229B2 (en)	2002-03-07	2004-11-30	Blanchette Rockefeller Neurosciences Institute	Methods for Alzheimer's Disease treatment and cognitive enhancement
US20050065205A1 (en) *	2002-03-07	2005-03-24	Daniel Alkon	Methods for Alzheimer's disease treatment and cognitive enhance
US20080004332A1 (en) *	2002-03-07	2008-01-03	Alkon Daniel L	Methods for alzheimer's disease treatment and cognitive enhancement
US8030300B2 (en)	2003-06-10	2011-10-04	Georgetown University	Ligands for nicotinic acetylcholine receptors, and methods of making and using them
TW201207390A (en)	2004-05-18	2012-02-16	Brni Neurosciences Inst	Method for screening agent for antidepressant activity
EP1924712B1 (en) *	2005-08-03	2018-10-03	The Johns Hopkins University	Methods for characterizing and treating cognitive impairment in aging and disease
US8510055B2 (en)	2005-08-03	2013-08-13	The Johns Hopkins University	Methods for characterizing and treating cognitive impairment in aging and disease
WO2007139818A2 (en)	2006-05-22	2007-12-06	The Board Of Trustees Of The Leland Stanford Junior University	Pharmacological treatment of cognitive impairment
US10954231B2 (en)	2006-10-16	2021-03-23	Bionomics Limited	Anxiolytic compounds
AU2013202426B2 (en) *	2006-10-16	2015-08-06	Bionomics Limited	Novel anxiolytic compounds
SI2074123T1 (sl)	2006-10-16	2013-03-29	Bionomics Limited	Nove anksiolitične spojine
CN101848726A (zh)	2007-02-09	2010-09-29	布朗歇特洛克菲勒神经科学研究所	苔藓抑素、苔藓抑素类似物和其它相关物质对头部创伤引起的记忆缺陷和脑损伤的疗效
EP2268639A2 (en) *	2008-05-22	2011-01-05	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318695A1 (en) *	2008-06-19	2009-12-24	Vinod Kumar Kansal	Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) *	2008-07-10	2010-01-14	Teva Pharmaceutical Industries Ltd.	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US10206921B2 (en) *	2009-06-03	2019-02-19	The Regents Of The University Of California	Methods and compositions for treating a subject for central nervous system (CNS) injury
US8178537B2 (en) *	2009-06-22	2012-05-15	Teva Pharmaceutical Industries Ltd.	Solid state forms of varenicline salts and processes for preparation thereof
AU2011328993B2 (en)	2010-11-15	2017-03-02	Agenebio, Inc.	Pyridazine derivatives, compositions and methods for treating cognitive impairment
EP2680842A4 (en) *	2011-03-02	2014-10-29	Bionomics Ltd	METHOD FOR THE TREATMENT OF A DISEASE OR A SENSE OF THE CENTRAL NERVOUS SYSTEM
WO2012116415A1 (en)	2011-03-02	2012-09-07	Bionomics Limited	Novel small-molecules as therapeutics
CN103649086A (zh)	2011-05-12	2014-03-19	生态学有限公司	制备萘啶的方法
EP4032889B1 (en)	2013-12-20	2026-05-06	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3310785B1 (en)	2015-06-19	2024-11-20	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2019288382B2 (en)	2018-06-19	2024-07-25	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN116008442B (zh) *	2023-03-27	2023-06-30	上海赛默罗生物科技有限公司	α5-GABAA受体调节剂的合成中间体的杂质检测方法
CN116077459B (zh) *	2023-04-10	2023-07-07	上海赛默罗生物科技有限公司	α5-GABAA受体调节剂的胶囊剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP0003258A3 (en) *	1997-08-25	2001-05-28	Neurogen Corp Branford	Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
US6448246B1 (en) *	1999-05-25	2002-09-10	Neurogen Corporation	Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands

2002
- 2002-02-20 IL IL15746502A patent/IL157465A0/xx unknown
- 2002-02-20 EP EP02700509A patent/EP1363606A1/en not_active Withdrawn
- 2002-02-20 EA EA200300854A patent/EA200300854A1/ru unknown
- 2002-02-20 WO PCT/IB2002/000515 patent/WO2002069948A1/en not_active Ceased
- 2002-02-20 CN CNA028058046A patent/CN1494422A/zh active Pending
- 2002-02-20 NZ NZ527397A patent/NZ527397A/en unknown
- 2002-02-20 JP JP2002569125A patent/JP2004527500A/ja active Pending
- 2002-02-20 EE EEP200300422A patent/EE200300422A/xx unknown
- 2002-02-20 SK SK1075-2003A patent/SK10752003A3/sk not_active Application Discontinuation
- 2002-02-20 KR KR10-2003-7011366A patent/KR20030076717A/ko not_active Ceased
- 2002-02-20 CZ CZ20032338A patent/CZ20032338A3/cs unknown
- 2002-02-20 BR BR0207802-3A patent/BR0207802A/pt not_active IP Right Cessation
- 2002-02-20 OA OA1200300213A patent/OA12554A/en unknown
- 2002-02-20 PL PL02364081A patent/PL364081A1/xx not_active Application Discontinuation
- 2002-02-20 CA CA002439581A patent/CA2439581A1/en not_active Abandoned
- 2002-02-20 MX MXPA03007834A patent/MXPA03007834A/es unknown
- 2002-02-20 HU HU0303448A patent/HUP0303448A3/hu unknown
- 2002-02-26 US US10/083,743 patent/US20020193360A1/en not_active Abandoned
- 2002-02-26 PE PE2002000157A patent/PE20020927A1/es not_active Application Discontinuation
- 2002-02-26 DO DO2002000345A patent/DOP2002000345A/es unknown
- 2002-02-27 AR ARP020100693A patent/AR033425A1/es not_active Application Discontinuation
- 2002-02-27 UY UY27188A patent/UY27188A1/es not_active Application Discontinuation
- 2002-02-27 GT GT200200039A patent/GT200200039A/es unknown
- 2002-02-28 TN TNTNSN02018A patent/TNSN02018A1/fr unknown
- 2002-02-28 AP APAP/P/2002/002465A patent/AP2002002465A0/en unknown
- 2002-02-28 PA PA20028540701A patent/PA8540701A1/es unknown
2003
- 2003-08-07 IS IS6905A patent/IS6905A/is unknown
- 2003-08-11 ZA ZA200306193A patent/ZA200306193B/en unknown
- 2003-08-19 MA MA27286A patent/MA26999A1/fr unknown
- 2003-08-25 CR CR7059A patent/CR7059A/es not_active Application Discontinuation
- 2003-08-25 BG BG108131A patent/BG108131A/xx unknown
- 2003-08-28 NO NO20033821A patent/NO20033821L/no not_active Application Discontinuation
- 2003-09-01 EC EC2003004759A patent/ECSP034759A/es unknown
- 2003-12-02 US US10/727,934 patent/US20040082555A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20033821L (no)	2003-09-10
US20020193360A1 (en)	2002-12-19
KR20030076717A (ko)	2003-09-26
CZ20032338A3 (cs)	2004-08-18
MXPA03007834A (es)	2003-12-08
IS6905A (is)	2003-08-07
WO2002069948A1 (en)	2002-09-12
CR7059A (es)	2004-03-10
EE200300422A (et)	2004-02-16
US20040082555A1 (en)	2004-04-29
NZ527397A (en)	2005-05-27
TNSN02018A1 (fr)	2005-12-23
CA2439581A1 (en)	2002-09-12
PA8540701A1 (es)	2002-09-30
HUP0303448A3 (en)	2005-05-30
AR033425A1 (es)	2003-12-17
CN1494422A (zh)	2004-05-05
AP2002002465A0 (en)	2002-06-30
BR0207802A (pt)	2004-03-09
UY27188A1 (es)	2002-10-31
JP2004527500A (ja)	2004-09-09
EA200300854A1 (ru)	2004-02-26
HUP0303448A2 (hu)	2004-01-28
ZA200306193B (en)	2004-08-11
DOP2002000345A (es)	2002-12-15
PL364081A1 (en)	2004-12-13
MA26999A1 (fr)	2004-12-20
OA12554A (en)	2006-06-07
EP1363606A1 (en)	2003-11-26
ECSP034759A (es)	2003-10-28
SK10752003A3 (sk)	2004-08-03
GT200200039A (es)	2002-11-21
IL157465A0 (en)	2004-03-28
PE20020927A1 (es)	2002-10-30
NO20033821D0 (no)	2003-08-28

Publication	Publication Date	Title
AP2002002465A0 (en)	2002-06-30	Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or Vitamin E for the treatment of cognitive disorders.
WO2001085145A8 (en)	2001-12-13	A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
DE60134453D1 (de)	2008-07-31	Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
CO5370677A1 (es)	2004-02-27	Nuevos derivados heterociclicos de carbonil sustituido y su uso como ligantes receptores d3 de dopamina
AR016217A1 (es)	2001-06-20	Composicion farmaceutica que comprende un modulador dispositivo de un agonista receptor nicotinico, metodo para el tratamiento de un trastorno asociado conuna transmision reducida de nicotina, metodo para identificar un agonista repector nicotinico, uso de un modulador positivo de un agonista recept
MXPA02001306A (es)	2004-06-22	Composiciones farmaceuticas para el tratamiento de enfermedades del sistema nervioso central y otras enfermedades.
DE60044152D1 (de)	2010-05-20	Bupropion Metaboliten zur Behandlung von Angstzuständen
ATE492279T1 (de)	2011-01-15	Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
MA27863A1 (fr)	2006-04-03	Forme posologique à libération prolongée d'anesthésiques pour le traitement de la douleur
MXPA03006943A (es)	2005-04-29	Derivados de carbonilo sustituidos heterocicliclos y su uso como ligandos para el receptor d3 de la dopamina.
PA8597301A1 (es)	2004-09-16	Derivados de imidazol-4-il-etinil-piridina
MY135838A (en)	2008-07-31	Methods for the treatment of mental disorders
MY124786A (en)	2006-07-31	Bis-arylsulfones
AP2002002420A0 (en)	2002-03-31	Fused pyrrolecarboxamides: gaba brain receptor ligands.
TW200631956A (en)	2006-09-16	Azabenzoxazoles for the treatment of CNS disorders
CO5390077A1 (es)	2004-04-30	Nuevos derivados heterociclicos de urea y su uso como ligantes receptores d3 de dopamina
BR0104345A (pt)	2002-05-21	Tratamento combinado para a depressão e ansiedade
ATE261443T1 (de)	2004-03-15	3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen
BR0005319A (pt)	2001-07-17	Tratamento combinado para depressão e ansiedade
DK1192161T3 (da)	2003-08-25	Chromeno[4,3,2-de]isoquinoliner som kraftige dopaminreceptorligander
ES2176642T3 (es)	2002-12-01	Utilizacion de la sulbutiamina para la obtencion de composiciones farmaceuticas utiles en el tratamiento de ciertos t rastornos psicomotores y psicointelectuales.
DE60129846D1 (de)	2007-09-20	Isochinolin-aroylpyrrole für die behandlung von krankheiten des zentralnervensystems
UA34141A (uk)	2001-02-15	Спосіб отримання лікарського препарату з ембріонального мозку
NZ776101B2 (en)	2025-01-28	Extended release pharmaceutical compositions of levetiracetam
CL2003002467A1 (es)	2005-02-11	Compuestos derivados de bencilpiperazina y bencilpiperidina; metodo de preparacion; composicion farmaceutica; y uso de los compuestos para los trastornos del snc tales como enfermedad de parkinson, agresion, trastornos de ansiedad, autismo, depresion